Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy by BROMAN, M et al.
Phosphate-containing dialysis solution prevents
hypophosphatemia during continuous renal
replacement therapy
M. BROMAN
1,O .C ARLSSON
2,H .F RIBERG
1,A .W IESLANDER
2 and G. GODALY
2
1Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden and
2Gambro Lundia AB, Lund, Sweden
Background: Hypophosphatemia occurs in up to 80% of
the patients during continuous renal replacement therapy
(CRRT). Phosphate supplementation is time-consuming
and the phosphate level might be dangerously low before
normophosphatemia is re-established. This study evalu-
ated the possibility to prevent hypophosphatemia during
CRRT treatment by using a new commercially available
phosphate-containing dialysis ﬂuid.
Methods: Forty-two heterogeneous intensive care unit
patients, admitted between January 2007 and July 2008,
undergoing hemodiaﬁltration, were treated with a new
Gambro dialysis solution with 1.2mM phosphate (Phox-
ilium) or with standard medical treatment (Hemosol B0).
The patients were divided into three groups: group 1
(n 5 14) receiving standard medical treatment and intra-
venous phosphate supplementation as required, group 2
(n 5 14) receiving the phosphate solution as dialysate
solution and Hemosol B0 as replacement solution and
group 3 (n 5 14) receiving the phosphate-containing solu-
tion as both dialysate and replacement solutions.
Results: Standard medical treatment resulted in hypopho-
s p h a t e m i ai n1 1o f1 4o ft h ep a t i e n t s( g r o u p1 )c o m p a r e d
with ﬁve of 14 in the patients receiving phosphate solution
as the dialysate solution and Hemosol B0 as the replace-
ment solution (group 2). Patients treated with the phos-
phate-containing dialysis solution (group 3) experienced
stable serum phosphate levels throughout the study.
Potassium, ionized calcium, magnesium, pH, pCO2 and
bicarbonate remained unchanged throughout the study.
Conclusion: The new phosphate-containing replacement
and dialysis solution reduces the variability of serum
phosphate levels during CRRT and eliminates the inci-
dence of hypophosphatemia.
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T
HE majority of patients on continuous renal
replacement therapy (CRRT) will require phos-
phate supplementation shortly after CRRT initia-
tion.
1 One reason is that critically ill patients
present several conditions predisposing hypopho-
sphatemia such as sepsis, alcohol withdrawal,
malnutrition, catecholamines, intravenous glucose
infusion, hyperventilation, diuretics and rhabdo-
myolysis.
2–4 Another reason is the CRRT technique
that achieves high clearance of small solutes, such
as phosphate.
5–9 In addition, low serum phosphate
levels may also occur in the setting of extracellular
to intracellular shifts that occur with respiratory
alkalosis, high blood concentrations of stress hor-
mones (i.e., insulin, glucagon, adrenalin, cortisol)
and with refeeding syndrome.
As phosphate is a constituent of enzymes and
intermediate phosphorylated compounds, it plays
a key role in cellular metabolism and is essential in
several biological processes. Serum phosphate con-
centration is maintained between 0.81 and
1.45mmol/l. By convention, hypophosphatemia is
often graded as mild ( o0.81mmol/l), moderate
( o0.61mmol/l) and severe ( o0.32mmol/l). Severe
hypophosphatemia has been linked to increased
mortality in surgical intensive care patients
7 and
was recently shown to serve as an independent
mortality predictor in sepsis.
10 Symptoms of hypo-
phosphatemia are usually only seen in patients
with moderate or severe hypophosphatemia and
include ventilatory muscle weakness, cardiac
failure, insulin resistance, hemolysis, impaired
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doi: 10.1111/j.1399-6576.2010.02338.xplatelet and white blood cell function, rhabdomyo-
lysis, and, in rare cases, neurologic disorders.
3,11–17
However, all these alternations have been shown
to reverse by simply correcting the phosphate
levels.
3,7,12,13,18–20 Phosphate is supplemented in-
travenously in symptomatic patients, but phos-
phate has also been added directly to the
dialysate and replacement ﬂuids,
1,21,22 with a risk
of precipitation with calcium.
The development of many electrolyte distur-
bances in the intensive care unit (ICU) could be
prevented by the use of better adapted dialysis
ﬂuids. This study evaluated the possibility to achieve
and maintain a normal phosphate balance over time
in patients on CRRT by using a new phosphate-
containing dialysis ﬂuid and replacement ﬂuid.
Methods
Fluid composition and study design
We used a new phosphate-containing solution for
dialysis that in addition to standard electrolytes also
contains 4.0mmol of potassium and 1.2mmol of
phosphate (Phoxilium, Gambro Lundia AB, Lund,
S w e d e n ,T a b l e1 ) .A sac o n t r o l ,w eu s e do u rr o u t i n e
dialysis solution that does not contain phosphate
(Hemosol B0, Gambro Lundia AB, Table 1). At our
ICU at Lund University Hospital we applied three
regimes, half a year each, for all patients requiring
CRRT treatment. The treatment mode used was
CVVHDF. During the ﬁrst period (group 1), all the
patients received dialysate solution and replacement
solution that did not contain phosphate (Hemosol
B0), during the next half year (group 2), all patients
requiring CRRT treatment received the phosphate-
containing solution as dialysis solution and a phos-
phate-free replacement solution (Hemosol B0) and
ﬁnally during the last half year period (group 3), the
patients received the phosphate-containing solution
both as a dialysis solution and as a replacement
solution. Blood sampling was performed according
to normal routines at our department, but the phy-
sicians in charge continuously modiﬁed the CRRT
treatment settings and the phosphate supplementa-
tion according to the patients’ ongoing clinical needs.
The physicians treating the patients did not have
knowledge of the study setting during the treat-
ments, but they were fully aware of the ﬂuids and
their contents.
Patients and CRRT treatments
After acceptance by the Regional Ethical Review
Board (DNR 570/2008), Lund University, Sweden,
we evaluated retrospectively the ﬁrst 14 patients
who did not fulﬁll the exclusion criteria in each
group, a total of 42 consecutive patients (Table 2).
Patients were excluded if they had chronic kidney
disease, if they had received intermittent dialysis
before the ICU stay, if the CRRT treatment lasted
Table 1
Fluid composition.
Hemosol B0
(mmol/l)
Phosphate containing
dialysis solution (mmol/l)
Bicarbonate 32 30
Lactate 3 0
Calcium 1.75 1.25
Magnesium 0.5 0.6
Potassium 0 4
Sodium 140 140
Phosphate 0 1.2
Chloride 109.5 115.9
Table 2
Main diagnoses leading to intensive care of the study groups.
Main diagnoses Group 1 Group 2 Group 3
Septic shock 5 8 7
Pneumonia 2 1 0
Cardiac insufﬁciency 0 0 3
Cardiac arrest 1 0 2
Major intoxication 1 0 1
Rupture of aortic aneurysm 0 0 2
Myocardial infarction 0 0 1
Cardiogenic shock 0 0 1
Sclerosis cholangitis 0 0 1
Unspeciﬁed respiratory failure 1 0 0
Obstructing malignant intestinal tumour 1 0 0
Epilepsy 1 0 0
Unspeciﬁed muscle disease 0 0 1
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40o10h or if they were under the age of 18 years. In
all patients, the Gambro Prismaﬂex CRRT machine
with the CVVHDF modality and a Hospal M100
ﬁlter (Hospal Industrie, Meyziew, France) was used.
The blood ﬂow, the dialysis ﬂuid ﬂow, the replace-
ment ﬂuid ﬂow, the anticoagulation used and the
ﬂuid removal were set according to the patients’
conditions and requirements. Of the replacement
ﬂuid, 500ml/h was postﬁlter and the rest was
preﬁlter in each treatment according to the general
standard at the department. Intravenous phosphate
additionwas prescribed when serum phosphate was
o0.8mmol/l, also according to the general standard
at the department. Nutrition was given only if the
patients were hemodynamically stable as parenteral
or enteral or both during the study period.
Clinical parameters of the patients
All patients had regular measurements of serum
sodium, potassium, ionized calcium, pH, pCO2 and
bicarbonate either from an arterial line or from a
central venous line before the start and regularly
every fourth hour all through the CRRT treatment
during 1, 2, 3, 4 and maximum 5 days. For phos-
phate and magnesium analyses, blood samples
were taken at 5:00 hours in the morning and at
17:00 hours in the afternoon before the start and
during the CRRT treatment days. Blood samples
were analyzed at the hospital laboratory (Labora-
tory for Clinical Chemistry, Lund University Hos-
pital, Lund, Sweden). The results are presented as
means   SD for normal distributed data, median
and range for remaining data.
In addition, baseline characteristics of study pa-
tients and delivered CRRT were registered (Table 3).
Hypophosphatemia has been deﬁned as condition
where the serum phosphate level is o0.81mmol/l.
Statistics
One-way repeated measures analysis of variance
was used. The statistical program used was Sigma-
Stat, version 3.5, for Windows XP. Differences were
considered to be signiﬁcant for Po0.05.
Results
Main diagnoses leading to intensive care of the
study groups, baseline characteristics, timing of
initiation of CRRT, ultraﬁltration rate, duration of
the CRRT and anticoagulation were statistically
similar between the three groups (Tables 2 and 3).
The incidence of hypophosphatemia occurred in
11 of 14 patients in group 1, where the patients did
not receive the phosphate-containing dialysis solu-
tion, but received phosphate intravenously based
on the serum phosphate values (Fig. 1). In group 2,
where the patients received a phosphate-contain-
ing solution as the dialysis solution and a phos-
Table 3
Baseline characteristics of study patients and delivered CRRT.
Group 1 Group 2 Group 3
Demographics*
Age (years) 63 (43–86) 68 (37–88) 67 (53–83)
Weight (kg) 80 (53–116) 86 (56–124) 79 (41–130)
Male sex, n (%) 7 (50) 7 (50) 5 (36)
APACHE II* 28.1 (19–44) 26 (13–36) 23.2 (15–29)
RIFLE score, points*,w 37 39 39
Delivered CRRT*
CRRT treatment duration (h) 82 (17–278) 115 (37–207) 96 (29–210)
CRRT treatment mode CVVHDF CVVHDF CVVHDF
Efﬂuent ﬂow (ml/kg/h) calculated on active treatment time*,z 23.7 (13–45) 21.9 (15–30) 18 (10–20)
Proportion of ordered dose delivered* 85.3% 87.5% 91.8%
Anticoagulation* None 3 None 2 None 2
Heparine 9 Heparine 11 Heparine 10
Prostacycline 1 Prostacycline 1 Prostacycline 2
Phosphate supplementation§ (mmol/CRRT treatment day) 11 (0–35) 3 (0–13) 0 (0)
*Differences between groups were not statistically signiﬁcant. Numbers in parentheses are range, unless stated otherwise.
wWe scored RIFLE-risk (R, risk; I, injury; F, failure; L, loss of kidney function; E, end-stage kidney disease) as 1, injury as 2, and failure
as 3.
zThe dialysis dose in CRRT is expressed in terms of ml of efﬂuent (dialysate1ultraﬁltrate) per kg of body weight (BW) per hour (ml/kg/
h).
23
§Statistical differences were as follows: between groups 1 and 2 (P50.046), between groups 1 and 3 (P   0.001), and between
groups 2 and 3 (P50.003).
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41phate-free solution as the replacement solution,
ﬁve of 14 patients had at least one episode of
hypophosphatemia (Fig. 1). No episodes of hypo-
phosphatemia were detected in group 3.
The serum phosphate level was 1.90mmol/l at
baseline and 0.99mmol/l during CRRT treatment in
group 1. In group 2, the corresponding values were
1.54 and 1.20mmol/l, and in group 3, they were 1.83
and 1.43mmol/l (Table 5). However, due to the
simultaneous intake of enteral/parenteral solutions,
two of 14 of the patients in group 3 had a temporary
increase in serum phosphate (o1.9mmol/l), but
there were no cases of hyperphosphatemia that
required a withdrawal of the phosphate-containing
dialysis solution from the treatment.
Phosphate intake was from nutrition and from
intravenous supplementation. The average phos-
phate input calculated from the total nutrition was
18mmol/CRRT treatment/day for all groups.
Short-acting insulin was administered as infusion
in order to achieve a blood glucose level between 5
and 8mmol/l. Phosphate was supplemented in-
travenously if serum phosphate declined to
o0.80mmol/l. In group 1, the average phosphate
supplementation was 10mmol/CRRT treatment/
day. In group 2, the average supplementation was
5mmol/CRRT treatment and day, and in group 3,
there was no intravenous supplementation.
There was a decline in phosphate levels during
CRRT treatment in both groups 1 and 2. In group 1,
serum phosphate declined constantly, although the
patients received phosphate supplementation in-
travenously (Fig. 2). In group 2, the phosphate
levels were unstable and reached a low level in
the end of the study. In group 3, where the patients
received a phosphate-containing solution both as
the dialysis solution and the replacement solution,
none of the patients had episodes of hypopho-
sphatemia (Fig. 2). Phosphate remained stable in
this patient population during the entire study.
For group 3, we also evaluated any adverse event
in sodium, potassium and magnesium homeostasis.
There was a signiﬁcant increase in sodium
(P   0.001) and a slight increase in ionized calcium
(P50.029), whereas potassium and magnesium re-
mained stable during the entire study as summar-
ized in Table 4. A comparison between the study
groups revealed that there was a signiﬁcant differ-
ence in phosphate (P   0.001), ionized calcium
(P50.004) and bicarbonate (P50.045) between the
groups (Table 5). The pH and pCO2 measurements
were obtained at baseline and rapidly declined
toward normal values after starting the CRRT treat-
ment and remained essentially unchanged during
the treatment in all groups (Table 4).
Discussion
This study demonstrates that the new phosphate-
containing dialysis solution is safe, reduces the
variability of serum phosphate levels during
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Fig. 1. Events of hypophosphatemia during the continuous renal
replacement therapy. Treatment with the phosphate-containing
solution for dialysis resulted in no episodes of hypophosphatemia.
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Fig. 2. Serum phosphate levels during the continuous renal
replacement therapy treatment. Group 1, receiving Hemosol B0
(diamond), group 2, receiving the phosphate-containing dialysis
ﬂuid as the dialysis ﬂuid and Hemosol B0 as the replacement ﬂuid
(triangle), and group 3, receiving the phosphate-containing dia-
lysis ﬂuid (square). Groups 2 and 3 were statistically compared
with group 1. n514 patients/group, **Po0.01, ***Po0.001.
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42CRRT and reduces the incidence of hypophos-
phatemia.
Various protocols for intravenous phosphate
supplementation have been studied in the last 30
years. Today, there is a trend toward the use of
larger and faster boluses of phosphate because of
high failure of repletion (20–70%) and the need for
additional phosphate administration.
24–31 Authors
usually agree that larger amounts of phosphate are
needed to correct total body deﬁcit, but their fear of
adverse reactions has prompted a restrained atti-
tude. Recent studies on ICU patients conﬁrm that a
relatively rapid infusion of potassium phosphate is
safe if baseline serum potassium is below
4.5mmol/l.
1 The infusion rate is thus consequently
limited by the serum potassium levels, and also by
serum calcium levels, as high phosphate serum
levels could induce hypocalcemia, as phosphate
could precipitate with calcium in blood vessels and
tissues. Recently, phosphate has been injected into
dialysis solutions during treatment, but there is a
risk of precipitation.
1,21,22 We evaluated whether
phosphate-containing solutions for dialysis and
replacement simplify phosphate replacement even
further.
The frequency of phosphate disturbances in
critically ill patients is high, although the ﬁgure
varies considerably depending on the study, be-
tween 8.8% and 80%.
32,33 In our study, the inci-
dence of hypophosphatemia during CRRTwas 79%
in the control group. The incidence of hypopho-
sphatemia was lower (35%) in patients receiving
the phosphate-containing solution as the dialysis
solution and Hemosol B0 as the replacement solu-
tion. There were no episodes of hypophosphatemia
in patients receiving only the phosphate-containing
solution, but there was an incidence of mild
(>1.9mmol/l) hyperphosphatemia in 14% of these
patients. This is probably due to the simultaneous
intake of nutritional support, but the phosphate
levels were only marginally elevated without phy-
siological consequences and did not require with-
drawal of the phosphate-containing dialysis
solution from the patient.
The amount of phosphate required to correct
total body deﬁcit is variable and depends on the
cause of hypophosphatemia and the chronicity of
the process.
3,11,24 The many physiological rearran-
gements in ICU patients may explain the need for
larger amounts required for repletion. In our study,
phosphate addition was necessary for patients in
groups 1 and 2. This is representative of our
experience, where the majority of patients on
CRRT require phosphate supplementation shortly
after CRRT initiation despite nutritional support.
Malnourished alcoholic patients have a larger def-
icit due to long-standing negative phosphate bal-
ance. Malnutrition induces a re-feeding syndrome
that has been reported after only 48h of fasting in
the ICU.
2 The distribution volume for phosphate
might be increased,
24 while insulin, carbohydrate,
and catecholamine administration act to decrease
the serum phosphate concentration.
2,3,11,34
The incidence of hypophosphatemia in this
study was 10% of the 42 patients before the start
of CRRT. The incidence of hyperphosphatemia was
Table4
Serum solute concentrations (mmol/l) during CRRT with the phosphate containing dialysis ﬂuid for patients in group 3.
Day on CRRT Before 1 2 3 4 5
Sodium* 134.0   5 135.0   3 135.2   2 135.0   2 135.7   2 135.8   3
Potassiumw 4.06   0.5 4.10   0.4 4.14   0.3 4.23   0.3 4.39   0.4 4.49   0.5
Ionised calciumz 1.11   0.08 1.10   0.05 1.15   0.07 1.17   0.06 1.16   0.05 1.17   0.06
Magnesiumw 1.1   0.4 1.0   0.2 1.1   0.2 0.7   0.2 0.9   0.1 1.0   0.3
*P   0.001 within the group.
wDifferences within the group were not statistically signiﬁcant.
zP50.029 within the group.
Table5
Serum values (mmol/l, kPa) during CRRT with the phosphate-
containing dialysis ﬂuid.
Group Group 1 Group 2 Group 3
Before During Before During Before During
Phosphate* 1.90 0.99 1.54 1.20 1.83 1.43
Ionized Caw 1.10 1.24 1.13 1.19 1.11 1.15
pHz 7.24 7.40 7.30 7.36 7.32 7.36
pCO2z 5.59 5.27 5.81 5.77 6.51 5.27
Bicarbonate§ 18 24 21 23 21 22
Mean values of each day of all the patients.
*P   0.001 between the groups during the CRRT treatment.
wP50.004 between the groups during the CRRT treatment.
zDifferences between the groups were not statistically signiﬁ-
cant.
§P50.045 between the groups during the CRRT treatment.
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4352%, which is slightly lower than that found in
other studies, where 65–80% of patients present
hyperphosphatemia before the start of the
CRRT.
8,35 Phosphate was within normal limits in
3 8 %o fp a t i e n t se v e nb e f o r et h eb e g i n n i n go f
CRRT. The new dialysis ﬂuid contains 30mM
bicarbonate compared with 32mM in Hemosol
B0. With prescribed CRRTclearances of   20ml/
kg/h, most acid–base disturbances can be mana-
ged with bicarbonate compositions of 25–
35mM.
36 T h en o r m a ls e r u mr a n g ef o rb i c a r b o n a t e
is 22–30mmol/l, which was achieved in patients
in all groups, although the increase in group 1
was most signiﬁcant. Ionized calcium increased in
all groups during treatment time, but the increase
w a sl e s sm a r k e di ng r o u p s2a n d3 .T h e r ei sa
possibility that the slow increase in bicarbonate
and ionized calcium could reﬂect the differences
in the ion content between Hemosol B0 and the
phosphate-containing dialysis ﬂuid, although
these differences could also be due to the limita-
tions of this study. The fact that this was a retro-
spective observational study, without other
intervention but for the dialysis solutions, means
that bias due to the patients’ illnesses and due to
other treatments could affect ion concentrations.
Even the phosphate concentration in parenteral
and enteral nutrition cannot be completely ex-
cluded, although this would not alter the basic
results of the study.
The next objective of the study was to evaluate
whether the administered phosphate could alter
calcium and potassium homeostasis. Phosphate
could theoretically precipitate with calcium, which
could lead to hypocalcemia in the patients. We
found that the phosphate-containing dialysis ﬂuid
did not induce hypocalcemia during CRRT. An-
other important concern was whether this ﬂuid
would cause potassium overload, as potassium
phosphate is used instead of sodium phosphate.
We found that the phosphate-containing dialysis
ﬂuid did not induce hyperkalemia either. Potas-
sium phosphate was favored over sodium phos-
phate because potassium usually has to be added
to CRRT solutions. In addition, there were no
disturbances of magnesium levels.
The present study shows that by using the phos-
phate-containing ﬂuid both as the dialysis ﬂuid and
the replacement ﬂuid, we could eliminate the epi-
sodes of hypophosphatemia. The new phosphate-
containing dialysis ﬂuid simpliﬁed the phosphate
control and avoided rapid phosphate ﬂuctuations
with intravenous bolus administration.
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